✦ LIBER ✦

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment

✍ Scribed by Seto, Wai-Kay; Liu, Kevin; Wong, Danny Ka-Ho; Fung, James; Huang, Fung-Yu; Hung, Ivan Fan-Ngai; Lai, Ching-Lung; Yuen, Man-Fung

Book ID: 122918913
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 879 KB
Volume: 59
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2013.06.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Kinetics of hepatitis B surface antigen

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients

✍ Karsten Wursthorn; Mechthild Jung; Antonio Riva; Zachary D. Goodman; Patricia Lo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 565 KB

Undetectable HBV DNA at month 12 of ente

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years

✍ G. L.-H. Wong; V. W.-S. Wong; H.-Y. Chan; P. C.-H. Tse; J. Wong; A. M.-L. Chim; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB

Extended lamivudine treatment in patient

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

✍ Nancy W.Y. Leung; Ching-Lung Lai; Ting-Tsung Chang; Richard Guan; Chuan-Mo Lee; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

20 THREE YEARS OF TENOFOVIR DISOPROXIL F

20 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103)

✍ M. Rizzetto; P. Marcellin; E.J. Heathcote; J. Sorbel; E. Mondou; J. Anderson; F. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d